Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer

Open access
Li, Zhongwu, Wang, Yanling, Zhu, Yumin, Yuan, Chunping, Wang, Dongmiao, Zhang, Wei, Qi, Bin, Qiu, Jin, Song, Xiaomeng, Ye, Jinhai, Wu, Heming, Jiang, Hongbing, Liu, Laikui, Zhang, Yuan, Song, Liang-Nian, Yang, Jianrong, Cheng, Jie·2015·Molecular Oncology

Abstract

The Hippo pathway has emerged as a fundamental regulator in tissue growth, organ size and stem cell functions, and tumorigenesis when deregulated. However, its roles and associated molecular mechanisms underlying oral squamous cell carcinoma (OSCC) initiation and progression remain largely unknown. Here, we identified TAZ, the downstream effector of Hippo signaling, as a novel bona fide oncogene by promoting cell proliferation, migration/invasion and chemoresistance in OSCC. TAZ promoted epithelial‐to‐mesenchymal transition (EMT) and also was involved in TGF‐β1‐induced EMT in oral cancer cells. Furthermore, enriched TAZ sustained self‐renewal, maintenance, tumor‐seeding potential of oral cancer stem cells (CSCs). Remarkably, enforced TAZ overexpression conferred CSCs‐like properties on differentiated non‐CSCs and fueled phenotypic transition from non‐CSCs to CSCs‐like cells. Mechanistically, TAZ‐TEADs binding and subsequent transcriptional activation of EMT mediators and pluripotency factors are presumably responsible for TAZ‐mediated EMT and non‐CSCs‐to‐CSCs conversion. Importantly, aberrant TAZ overexpression was found to be associated with tumor size, pathological grade and cervical lymph node metastasis, as well as unfavorable prognosis. Pharmacological repression of TAZ by simvastatin resulted in potent anti‐cancer effects against OSCC. Taken together, our findings have revealed critical links between TAZ, EMT and CSCs in OSCC initiation and progression, and also established TAZ as a novel cancer biomarker and viable druggable target for OSCC therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molonc.2015.01.007

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 169

Metadata

Authors
Li, Z., Wang, Y., Zhu, Y., Yuan, C., Wang, D., Zhang, W., Qi, B., Qiu, J., Song, X., Ye, J., Wu, H., Jiang, H., Liu, L., Zhang, Y., Song, L.-N., Yang, J., & Cheng, J.
Venue
Molecular Oncology
Publisher
Wiley
Published
2015-02-09
Volume
9
Issue
6
Pages
1091-1105
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2091183805
Cited by
169
References
4
FWCI
7.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. https://app.cochat.ai/papers/10.1016/j.molonc.2015.01.007
The paper
Li, Z., Wang, Y., Zhu, Y., Yuan, C., Wang, D., Zhang, W., Qi, B., Qiu, J., Song, X., Ye, J., Wu, H., Jiang, H., Liu, L., Zhang, Y., Song, L.-N., Yang, J., & Cheng, J. (2015). The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Molecular Oncology. https://doi.org/10.1016/j.molonc.2015.01.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.